For the roughly 30,000 Americans living with amyotrophic lateral sclerosis at any given time, the treatment menu is short and grim. Riluzole, approved in 1995, extends survival by a few months. Edaravone, approved in 2017, slows functional decline modestly in a subset of patients. Relyvrio, briefly a fourth option, was withdrawn from the U.S. market in 2024 after its confirmatory Phase 3 missed. Most patients still progress to respiratory failure within three to five years of diagnosis, and standard of care remains largely supportive: multidisciplinary clinics, non-invasive ventilation, feeding support, and palliative planning. It is into that very thin field that Canurta Therapeutics, a four-year-old biotech based in Brampton, Ontario, is preparing to bring CNR-401, a botanical drug candidate derived from hemp polyphenols called cannflavins A and B [Canurta Therapeutics].
Canurta says it submitted Pre-IND and Orphan Drug Designation applications for CNR-401 to the FDA in February 2025, with Phase 2 trials targeted for later in the year [Canurta Therapeutics] [GlobeNewswire]. Orphan designation, if granted, would unlock seven years of U.S. market exclusivity, tax credits on clinical research, and a waiver of the prescription drug user fee, meaningful tailwinds for a small company chasing a rare neurodegenerative indication. The company reports that CNR-401 has shown blood-brain barrier penetration and a favorable safety profile in mouse preclinical studies [Canurta Therapeutics], though those results have not been published in a peer-reviewed journal that the cited sources point to, and mouse data in ALS has a long history of failing to translate.
The bet
Canurta's core wager is that nature has already done a lot of the medicinal chemistry, and that AI can help find what human researchers have missed. The company's PolyKye platform screens botanical sources for novel bioactives and predicts synergies between compounds, a multi-target approach that fits how complex inflammatory and neurological diseases actually behave in the body [Canurta Therapeutics]. Cannflavins A and B, the lead chemistry, are non-cannabinoid polyphenols first characterized in the 1980s and shown in academic literature to have anti-inflammatory activity many times that of aspirin in vitro. Canurta has built its pipeline around them and around a broader library of plant-derived molecules, and reports that its first USPTO patent covering the PolyKye platform has issued, with additional applications pending globally [GlobeNewswire] [BioSpace].
The regulatory pathway matters here. CNR-401 is being developed as a botanical drug under the FDA's 2016 Botanical Drug Development guidance, the same framework that produced Veregen and Mytesi. That pathway accepts well-characterized mixtures rather than demanding a single purified active ingredient, which suits a multi-polyphenol therapeutic but also raises the bar on chemistry, manufacturing, and controls. Canurta's recent move to take operational control of a cGMP botanical extraction facility in Woodburn, Oregon, through its Canurta Naturals arm, reads as a direct response to that bar [Canurta Therapeutics].
Why it could matter
ALS drug development has been one of the most punishing corners of neurology, but it is also one where regulators have signaled real flexibility. The FDA's accelerated approval of Qalsody (tofersen) in 2023 on a biomarker endpoint, and the agency's willingness to engage with small sponsors through programs like the Rare Neurodegenerative Disease grant, have changed the calculus for early-stage companies. A botanical with a clean preclinical safety signal and a defensible IP position is the kind of asset that can attract a development partner if early human data holds.
Canurta has assembled roughly $13 million in cumulative funding across equity, convertible debt, and non-dilutive sources [BioSpace] [Investing News Network], including about $3.22 million in non-dilutive capital [Canurta Therapeutics]. That is modest by U.S. biotech standards but meaningful for a Canadian preclinical company, and the non-dilutive component, often grants and tax credits, has stretched the runway. The company has moved through both the Accelerator Centre and Creative Destruction Lab, the University of Toronto-affiliated program that has incubated a long list of Canadian deep-tech and life-sciences companies. PharmaDrug is named among its investors.
Cumulative funding | 13 | $M
Non-dilutive portion | 3.22 | $M
The team
Canurta was founded in 2021 by Akeem Gardner, who serves as CEO and is based in Brampton [Crunchbase]. Gardner, educated at the University of Kent, came to drug development from an entrepreneurial background that includes ventures in CPG, wellness, and media [LinkedIn]. The scientific bench around him includes Kelly Boddington and Eric Soubeyrand, who serve as mentors and managers and bring plant biochemistry credentials [LinkedIn]. Creative Destruction Lab has described the company as backed by a team with prior experience bringing botanical drugs to market [Creative Destruction Lab].
The honest counterfactual
The bear case on Canurta is straightforward and worth stating plainly: ALS has humbled far better-capitalized programs, mouse efficacy rarely predicts human benefit in this disease, and the preclinical data underpinning CNR-401 has been disclosed by the company rather than published in a peer-reviewed venue that the cited sources surface [Canurta Therapeutics]. The bull answer is that the company is not betting the franchise on a single Phase 2 readout. The PolyKye platform, now covered by an issued U.S. patent [GlobeNewswire], is designed to generate additional candidates across inflammatory indications, and the cGMP extraction capacity in Oregon gives Canurta a manufacturing moat that pure discovery shops lack. If CNR-401 stumbles, the platform and the IP are still standing.
What to watch
The next twelve months are the most consequential in Canurta's short history. The key milestones are an FDA response on the Pre-IND and Orphan Drug submissions, the actual initiation of the Phase 2 study in ALS patients, and any peer-reviewed publication of the preclinical package supporting CNR-401. A follow-on financing is the likely capital event, and the shape of that round, whether it brings in a specialist neurology investor or a strategic partner, will say a great deal about how the broader market reads the asset. For ALS patients and the clinicians who care for them, even a modestly positive signal from a novel mechanism would be welcome news in a field that has had very little of it.
Pulse Raman, Health and Bio Correspondent